Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I., Quinn, David I., Baum, Michael, Wood, Laura S., Tarazi, Jamal, Rosbrook, Brad, Arruda, Lillian Shahied, Cisar, Laura, Roberts, W. Gregory, Kim, Sinil, Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363524/
https://www.ncbi.nlm.nih.gov/pubmed/24595903
http://dx.doi.org/10.1007/s11523-014-0307-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363524/
https://www.ncbi.nlm.nih.gov/pubmed/24595903
http://dx.doi.org/10.1007/s11523-014-0307-z

Ejemplares similares